Becton, Dickinson and Company (BDX) Earnings Call Analysis

NYSE · Healthcare · Medical Instruments & Supplies

24/25

Growth 5 Margin 5 Expansion 5 Platform 4 Financial 5

latest quarter score

Earnings Reports

24
BD (BDX) Q3 2026: 8% Plant Productivity Drives Margin Resilience Amid Alaris and China Drag
August 06, 2026
24
BD (BDX) Q1 2026: $4B Waters Windfall Accelerates Share Buybacks, Reshapes MedTech Focus
June 16, 2026
24
BD (BDX) Q2 2026: $2B Buyback and 8% Productivity Underscore New Capital and Margin Playbook
May 08, 2026
22
BDX Q4 2025: $200M Cost-Out Initiative Accelerates Margin Expansion Amid Macro Headwinds
November 06, 2025
23
BDX Q3 2025: $4B Waters Deal Sets Stage for Margin Expansion and Focused MedTech Growth
August 07, 2025
18
BDX Q2 2025: $2.5B U.S. Manufacturing Investment Offsets 1% Organic Growth Slowdown
June 30, 2025
BD (BDX) Q4 2024: Free Cash Flow Surges 47% as Margin Expansion Anchors FY25 Outlook
November 07, 2024
BDX Q3 2024: Operating Margin Surges 220bps as BD Excellence Drives Structural Gains
August 01, 2024
BD (BDX) Q2 2024: Alaris Drives $300M+ Revenue Surge, Margin Expansion Signals FY25 Leverage
May 02, 2024
BD (BDX) Q1 2024: Margin Expansion Outpaces Revenue at 51.1%, Underpinning FY24 Guidance Raise
February 01, 2024
25
BDX Q4 2023: Six Growth Engines Now 25% of Sales, Offsetting China and FX Drag
November 09, 2023
BD (BDX) Q3 2023: Alaris Clearance Unlocks $400M Path, Margin Expansion Outpaces Inflation
August 03, 2023
Becton Dickinson (BDX) Q2 2023: Parata Acquisition Lifts Inorganic Growth to 125bps, Accelerating Platform Shift
May 04, 2023

Browse all companies